ProCE Banner Activity

CME

Expert Roundtable: Impact of Novel Therapies in Relapsed/Refractory CLL/SLL

Video

Faculty discuss the current and future impact of novel therapeutic options for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in this on-demand webcast.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 20, 2023

Expiration: November 19, 2024

No longer available for credit.

Share

Faculty

Jennifer R. Brown

Jennifer R. Brown, MD, PhD

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Florence Cymbalista

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme, LLC.

Lilly

Merck Sharp & Dohme, LLC

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Chronic Lymphocytic Leukemia (CLL)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the available evidence and expected clinical role of emerging CAR T-cell and BTKi therapies in R/R CLL/SLL

  • Plan individualized therapeutic strategies to optimize integration and sequencing of CAR T-cell therapies and noncovalent BTKis for patients with R/R CLL/SLL, including patient selection, referral to specialized CAR T-cell treatment centers, patient care coordination, and pretreatment/posttreatment supportive care

  • Implement proactive strategies for monitoring and managing toxicities associated with CAR T-cell therapies and noncovalent BTKis in patients with R/R CLL/SLL

  • Appraise ongoing clinical trials evaluating CAR T-cell therapy and noncovalent BTKis for the treatment of patients with CLL/SLL for appropriate and inclusive patient enrollment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jennifer R. Brown, MD, PhD

Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
CLL Center Director and Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Jennifer R. Brown, MD, PhD: consultant/advisor/speaker: AbbVie, Acerta/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Bristol Myers Squibb, EcoR1, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare, Kite, Loxo/Lilly, Magnet Biomedicine, Merck, Numab, Pharmacyclics; researcher: BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, TG Therapeutics; data and safety monitoring board: Grifols Therapeutics.

Florence Cymbalista, MD, PhD

Professor of Hematology
Sorbonne Paris Nord University
Bobigny, France

Florence Cymbalista, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Janssen, Lilly.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 20, 2023, through November 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.